Anzeige
Mehr »
Login
Freitag, 04.10.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Citibank´s $3.000-Gold-Prognose und die $60-Millionen-Wette, die den Mining-Sektor neu definieren könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 894565 | ISIN: GB0000536739 | Ticker-Symbol: 0LC
Tradegate
04.10.24
12:51 Uhr
67,50 Euro
0,00
0,00 %
1-Jahres-Chart
ASHTEAD GROUP PLC Chart 1 Jahr
5-Tage-Chart
ASHTEAD GROUP PLC 5-Tage-Chart
RealtimeGeldBriefZeit
66,5068,5014:36
67,0068,0014:36
PR Newswire
286 Leser
Artikel bewerten:
(1)

Ashtead Group Plc - Results of AGM

Ashtead Group Plc - Results of AGM

PR Newswire

LONDON, United Kingdom, September 04

Ashtead Group PLC

AGM Statement

4 September 2024

ASHTEAD GROUP PLC

("Ashtead" or the "Company")

AGM Statement & Results

AGM Statement & Results

At the Annual General Meeting ("AGM") of the Company held on 4 September 2024 at 11:30am, all resolutions put to shareholders were duly passed on a poll with the required majorities. The full text of each resolution is contained in the Notice of Annual General Meeting. [Resolutions 1 to 17 were passed as ordinary resolutions. Resolutions 18 - 21 were passed as special resolutions.]

As at 18:30 (UK time) on 3 September 2024, the number of voting shares of the Company was 437,298,807 ordinary shares, which was the total number of shares entitling the holders to attend and vote 'for' or 'against' all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll, every member present in person or by proxy has one vote for every share held.

ORDINARY RESOLUTIONS

Votes for (including discretionary votes)

% Votes for *

Votes against

% Votes against

Total no. of votes validly cast

% of Issued Share Capital voted

Votes

withheld **

1.

That the accounts for the year ended 30 April 2024, the directors' report and the auditors' report be adopted.

319,960,902

99.94

176,104

0.06

320,137,006

73.21%

1,729,414

2.

That the directors' remuneration report for the year ended 30 April 2024 be approved.

315,461,099

98.02

6,365,837

1.98

321,826,936

73.59%

39,483

3.

That the directors' remuneration policy set out in the Annual Report be approved

199,333,758

63.20

116,067,153

36.80

315,400,911

72.12%

6,465,508

4.

That the final dividend recommended by the directors of 89.25 US cents

per ordinary share for the year ended 30 April 2024 be declared payable on 10 September 2024 to holders of ordinary shares registered at the close of business on 9 August 2024.

321,753,141

99.97

94,135

0.03

321,847,276

73.60%

19,144

5.

That Paul Walker be re-elected as a director.

305,384,443

94.89

16,443,749

5.11

321,828,192

73.59%

38,228

6.

That Brendan Horgan be re-elected as a director.

321,828,217

99.99

16,145

0.01

321,844,362

73.60%

22,058

7.

That Michael Pratt be re-elected as a director.

319,425,228

99.25

2,402,970

0.75

321,828,198

73.59%

38,222

8.

That Angus Cockburn be re-elected as a director.

312,819,928

97.20

9,009,864

2.80

321,829,792

73.59%

36,628

9.

That Lucinda Riches be re-elected as a director.

276,916,470

86.04

44,913,099

13.96

321,829,569

73.59%

36,849

10.

That Tanya Fratto be re-elected as a director.

313,512,063

97.42

8,317,729

2.58

321,829,792

73.59%

36,628

11.

That Jill Easterbrook re-elected as a director.

312,704,023

97.16

9,125,769

2.84

321,829,792

73.59%

36,628

12.

That Renata Ribeiro be elected as a director.

312,371,694

97.41

8,295,613

2.59

320,667,307

73.33%

1,199,113

13.

That Roy Twite be elected as a director.

320,325,295

99.89

344,019

0.11

320,669,314

73.33%

1,197,106

14.

That PwC be appointed as auditor of the Company.

320,574,604

99.61

1,246,511

0.39

321,821,115

73.59%

45,305

15.

That the audit committee be authorised to agree the remuneration of the auditor of the Company.

321,760,060

99.98

73,929

0.02

321,833,989

73.60%

32,431

16.

Approval of the amendment to the rules of the Ashtead Group Long-Term Incentive Plan 2021

197,073,349

62.49

118,317,407

37.51

315,390,756

72.12%

6,475,663

17.

That the directors are authorised to allot the shares under section 551 (1) (a) and (b) of the Companies Act 2006.

310,490,547

96.47

11,345,471

3.53

321,836,018

73.60%

30,402

SPECIAL RESOLUTIONS

Votes for (including discretionary votes)

% Votes for *

Votes against

% Votes against

Total no. of votes validly cast

% of Issued Share Capital voted

Votes

withheld **

18.

That the directors be empowered to disapply the provisions of section 561 (1) to (6) of the Companies Act 2006.

301,169,011

93.59

20,630,839

6.41

321,799,850

73.59%

66,570

19.

That the directors be empowered to issue shares on a non

pre-emptive basis.

294,463,977

91.56

27,148,512

8.44

321,612,489

73.55%

253,931

20.

That the directors be authorised to make market purchases of the Company's shares under section 701 of the Companies Act.

314,106,605

97.61

7,707,185

2.39

321,813,790

73.59%

52,629

21.

That a general meeting other than an annual general meeting

may be called on not less than 14 clear days' notice.

313,089,701

97.28

8,745,621

2.72

321,835,322

73.60%

31,097

*

Includes discretionary votes

**

A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" and "against" a resolution.

The Ashtead Board is pleased to note that all resolutions were passed with the requisite majority of votes and welcomes the overwhelming support of the Company's shareholders for the majority of the resolutions proposed.

The Company notes the level of shareholder support for resolution 3 (Approval of the Directors' Remuneration Policy) and resolution 16 (the amendment to the rules of the Long-Term Incentive Plan). Prior to the AGM, the Remuneration Committee undertook an extensive consultation with its largest shareholders on the proposed Directors' Remuneration Policy (the "Policy") and its implementation.

The Committee received indications of broad support during this process, but also took into account the full range of feedback received. As described in the 2024 Annual Report, the Committee was very mindful of the need to balance sometimes divergent shareholder views with the particular context and circumstances for Ashtead, to ensure that remuneration policy continues to incentivise growth and long-term shareholder value creation. A number of changes were made as a direct result of shareholder feedback at the time. However, the Committee also concluded that the other aspects of the proposals remained appropriately aligned to the Company's stated principles of providing remuneration that is: market competitive; enables the Company to motivate and retain its talented leadership team; and rewards fairly its colleagues' contribution to Ashtead's future success.

The Company will now engage with its shareholders in respect of the implementation of the Policy. In accordance with the UK Corporate Governance Code the Company will publish an update on this further engagement within six months of the 2024 AGM.

Contact:

Ashtead Group plc

Will Shaw (Investment Manager) - 020 7726 9700

H/Advisors Maitland

Sam Cartwright - 020 7379 5151




© 2024 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.